MedPath

Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer

Registration Number
NCT03367182
Lead Sponsor
Yonsei University
Brief Summary

This study will evaluate the efficacy and safety profile, response rate, progression free survival, overall survival of bevacizumab (Avastin) added to chemotherapy in patients with epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma with disease progression within 6 months of platinum treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
50
Inclusion Criteria
  1. Patients who have histologically or cytologically confirmed recurrent epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer.
  2. Patients who have platinum-resistant disease (defined as having relapsed within 6 months of her last platinum-containing regimen)
  3. Patients who have underwent chemotherapy of either weekly paclitaxel + bevacizumab, topotecan + bevacizumab, pegylated liposomal doxorubicin + bevacizumab in 2nd line or 3rd line chemotherapy.
Read More
Exclusion Criteria
  1. Patients with previous treatment with bevacizumab.
  2. Patients who received bevacizumab combination therapy in 4th line or more chemotherapy.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Pegylated liposomal doxorubicin + bevacizumabPegylated liposomal doxorubicin-
Weekly paclitaxel + bevacizumabWeekly paclitaxel-
Topotecan + bevacizumabBevacizumab-
Pegylated liposomal doxorubicin + bevacizumabBevacizumab-
Weekly paclitaxel + bevacizumabBevacizumab-
Topotecan + bevacizumabTopotecan-
Primary Outcome Measures
NameTimeMethod
Progression free survival (PFS)36 months

PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the RECIST criteria

Incidence of Treatment-Emergent Adverse Events36 months

Safety and tolerability will be assessed in deaths, laboratory data, and vital signs. Number of participants with treatment-related adverse events as assessed by CTCAE version 4.0.

Secondary Outcome Measures
NameTimeMethod
overall survival (OS)36 months

Duration of overall survival was defined as the time from randomization to death of any cause. The OS data for participants for whom no death was captured in the clinical database were censored at the last time they were known to be alive.

Response rate36 months

Best Overall Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) by Modified RECIST until progression reported. Objective Response was determined by the investigator using modified RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR defined as complete disappearance of all target and non-target lesions and no new lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions.

Trial Locations

Locations (1)

Severance hospital

🇰🇷

Seoul, Korea, Republic of

Severance hospital
🇰🇷Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath